Wednesday, September 15, 2021

New FDA Records Show Purchases of Fetal Organs, Heads and Tissue for 'Humanized Mice' Project

Judicial Watch announced today that it received 198 pages of records and communications from the U.S. Food and Drug Administration involving "Humanized mice" research with human fetal heads, organs and tissue, including communications and contracts with human fetal tissue provider Advanced Bioscience Resources.

The records include an FDA generated contract with ABR, based on a "Requisition" it issued on July 27, 2012, for $12,000 worth of "Tissue procurement for humanized mice," indicates the requisition was for a "Non-competitive award." Although the initial award was for $12,000, the total estimated amount of funds allocated for the requisition was $60,000.

On September 24, 2018, the Trump FDA terminated its contract with ABR for human tissue purchases and began an audit of its acquisitions of baby body parts.

"Chopping up aborted human beings for their organs and tissue is a moral and legal outrage," said Judicial Watch President Tom Fitton.

In May 2021, this lawsuit uncovered FDA records showing the agency spent tens of thousands of taxpayer dollars to buy human fetal tissue from ABR. The tissue was used in creating "Humanized mice" to test "Biologic drug products." The records indicated the FDA wanted tissue purchases "Fresh; shipped on wet ice."

On August 3, 2021, Judicial Watch announced that it and The Center for Medical Progress, through a separate lawsuit, received 252 pages of new documents from the U.S. Department of Health and Human Services that reveal nearly $3 million in federal funds were spent on the University of Pittsburgh's quest to become a "Tissue Hub" for human fetal tissue ranging from 6 to 42 weeks' gestation.

The Pitt scientists note that, "All fetal tissue is collected through a collaborative process including Family Planning, Obstetrics and Pathology." Pitt anticipated "Being able to harvest and distribute quality tissue and cells [and] do not anticipate any major problems related to the acquisition and distribution of the tissues." Pitt's target goal "Is to have available a minimum of 5 cases per week of gestational age for ages 6-42 weeks."

https://www.judicialwatch.org/press-releases/new-fda-records-humanized-mice/ 

No comments: